Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Ixchiq is already approved in the US, Europe and Canada for use in individuals aged 18 years and older. The latest approval comes less than three weeks after Valneva shared positive results from a ...

IXCHIQ is the first licensed chikungunya vaccine, currently approved for adults 18 and older in the U.S., Europe, and Canada. Valneva plans to expand its use to adolescents and is seeking approval ...

ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for people aged 12–17 years old in ...

Valneva submitted label extension applications to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and Health Canada to potentially extend the use of Ixchiq to ...

Valneva submitted label extension applications to the U.S. Food and Drug Administration (FDA) 5, the European Medicines Agency (EMA) and Health Canada 6 to potentially extend the use of IXCHIQ ...

The approval is based on IXCHIQ®’s final pivotal Phase 3 data, published in The Lancet, which included more than 4,000 participants and demonstrated that a single dose of the live-attenuated ...

Valneva submitted label extension applications to the U.S. Food and Drug Administration (FDA) 5, the European Medicines Agency (EMA) and Health Canada 6 to potentially extend the use of IXCHIQ ® to ...